Kite (United States)

Recent papers from Kite (United States)

1. Determinants of response to CAR T cell therapy in a multicenter, multi-trial cohort analysis of patients with lymphomaNature Medicine · 2026
2. Clinical, economic, and quality-of-life outcomes of brexucabtagene autoleucel for the treatment of relapsed/refractory mantle cell lymphoma and B-cell acute lymphoblastic leukemia: A systematic literature review and meta-analysisJournal of Managed Care & Specialty Pharmacy · 2026
3. Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trialThe Lancet Oncology · 2018
4. Real-World Treatment Patterns of Patients with Large B-cell Lymphoma Over Time and into a Post-CAR T Approval EraBlood Advances · 2026
5. Real-world healthcare resource utilization (HCRU) following chimeric antigen receptor (CAR) T-cell therapy in US patients treated in new authorized treatment centers (ATCs) without FACT accreditation.Journal of Clinical Oncology · 2026
6. Urban Poverty in the Everyday Lives of Older People: A Qualitative Study ProtocolInternational Journal of Qualitative Methods · 2026
7. Data-informed optimization of CAR T-cell therapy long-term follow-upJournal for ImmunoTherapy of Cancer · 2026
8. Estimating the Survival Impact of Not Receiving CAR T-cell (CAR T) Therapy When Eligible in Patients with Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL) in the United States (US)Transplantation and Cellular Therapy · 2026
9. Anito-Cel’s D-Domain Binder Has a Fast Off-Rate and Contributes to Its Differentiated Pharmacology Profile in Multiple MyelomaTransplantation and Cellular Therapy · 2026
10. Targeted Lipid Nanoparticle Delivery of FAP-CAR mRNA Enables Potent In Vivo T-Cell Engineering Against Pancreatic TumorsCancer Immunology Research · 2026
11. Efficiency and robustness in three cortical areas: frontal pole cortex, dorsolateral prefrontal cortex and orbitofrontal cortexNeuroscience · 2025
12. Short-term costs associated with outpatient use of axicabtagene ciloleucel in second-line and above relapsed/refractory large B-cell lymphoma based on the zuma-24 clinical trialLeukemia & lymphoma/Leukemia and lymphoma · 2025
13. Cross-cultural adaptation and cognitive interview-based content validation of the English Participation Behaviour Questionnaire (PBQ), to measure participation in individuals with hand injuriesHand Therapy · 2025
14. Axicabtagene Ciloleucel in Combination With Atezolizumab in Patients With Refractory Diffuse Large B-cell Lymphoma: The Phase 1/2 ZUMA-6 TrialClinical Cancer Research · 2025
15. Axicabtagene Ciloleucel in Combination with Atezolizumab in Patients with Refractory Diffuse Large B-Cell Lymphoma: The Phase 1/2 ZUMA-6 TrialClinical Cancer Research · 2025
16. Access to Chimeric Antigen Receptor T-Cell Therapy in Patients With Diffuse Large B-Cell LymphomaJAMA Network Open · 2025
17. D3-GPC2-directed CAR T cells are safe and efficacious in preclinical models of neuroblastoma and small cell lung cancerClinical Cancer Research · 2025
18. Strategy for Validation of New Mycoplasma Nucleic Acid Detection Closed System and It Use in Routine Biopharmaceutical Manufcturing.PDA Journal of Pharmaceutical Science and Technology · 2025
19. Real-world outcomes of brexucabtagene autoleucel for relapsed or refractory mantle cell lymphoma: a CIBMTR analysisBlood Advances · 2025
20. Measurable residual disease detection after CAR-T may predict response in patients with large B-cell lymphomaBlood Advances · 2025